Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by Eoganachton Jan 23, 2020 12:38pm

92 Views

Post# 30589358

RE:RE:RE:RE:Dr. Kamat and Keytruda 1 Year CR in NMIBC Trial

Sorry - I was mis-remembering. It wouldn't have been Dr. Jewett. It might have been Dr. Alvaro Morales, a retired Canadian urologist who was instrumental in getting the approval of the FDA for the use of BCG for CIS in 1990.

Eoganacht wrote: Yes, it sounds like Dr. Kamat, Dr. Jewett and one other Canadian urologist.

enriquesuave wrote:
I suspect that the US Urologist referred to in this article was Dr Kamat.

"We recently spoke with three key opinion leaders (KOLs) to discuss Theralase’ PDT, including one US urologist who consulted on the FDA’s guidance, one Canadian urologist who was directly involved in achieving BCG approval by the FDA for treating bladder cancer and another Canadian urologist,” writes Uddin.

“All three KOLs commented that: (i) the Phase Ib clinical study data looked promising, (ii) the Phase II clinical study was well designed, and (iii) the Phase II clinical study should be sufficient to support an accelerated approval if it could replicate the Phase Ib clinical study results. In terms of competitive landscape, the two Canadian urologists were more bullish on Theralase’s PDT than other treatment modalities (such as PD-1 inhibitors) due to their safety and durability issues. The US urologist believed Theralase’s PDT could potentially be used in combination with PD-1 inhibitors to treat BCG- unresponsive NMIBC,” he said.

Yajne wrote: Thanks Eoganacht for reminding us of that infamous line from Dr. Kamat at the early termination of TLT's Ph1b trial. I have been concerned that he appears to have stronger allegiance to Merck than TLT in the BCG unresponsive trials, but maybe it's simply a case of timing. If I'm not mistaken Kamat is a PI for the Merck trial, which no doubt compensates him 'dearly' which is great while he waits for TLT's Ph2 to progress at it's current snails pace. I am hopeful that he will support TLT's results as strong when the time FINALLY comes...

The clinical data presented by Dr. Kulkarni suggests that the Theralase PDT treatment option may be just what the doctor ordered.”